Abstract: The invention provides (+)-?-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for use in reducing the life-shortening effect of Huntington's Disease in mammals. Also provided by the invention are (+)-?-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof for use in preventing or delaying the onset of late stage Huntington's Disease; or for use in preventing or delaying the onset of life-threatening symptoms or events exhibited during late stage Huntington's disease.
Abstract: Disclosed herein are new cyclic dinucleotide compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulation of immune response to disease, and induce Stimulator of Interferon Genes (STING) dependent type I interferon production and co-regulated genes in a human or animal subject are also provided for the treatment diseases such as cancer, particularly metastatic solid tumors and lymphomas, inflammation, allergic and autoimmune disease, infectious disease, and for use as anti-viral agents and vaccine adjuvants.
Type:
Grant
Filed:
June 27, 2022
Date of Patent:
July 16, 2024
Assignee:
Board of Regents, The University of Texas System
Inventors:
Maria Emilia Di Francesco, Philip Jones, Michael A. Curran
Abstract: Described herein are therapeutic pH responsive compositions useful for the treatment of cancer. The compositions involve combining a STING activating polymer micelle, such as PC7A, with a non-peptide STING agonist, such as cGAMP. Methods of administering these compositions in the treatment of cancer are also disclosed. These methods include administration of the pharmaceutical compositions by intratumoral injection in the treatment of solid tumors.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
July 16, 2024
Assignee:
The Board of Regents of The University of Texas System
Abstract: The present invention provides a composition and method for preventing the growth of and/or treating cancerous tumors and/or delaying onset of cancer from tumor-initiating cells. The composition includes an effective amount of a compound of Formula (I) or Formula (II): or any pharmaceutically acceptable salt thereof. The composition is administered alone or in combination with one or more chemotherapeutic agents, biological agents and/or anticancer agents. The method may include administering the composition of the present invention with or without the chemotherapeutic, biological, or other cancer treatment agent to a subject in need thereof intravenously, parenterally, nasally, topically or locally, orally, or by liposome, implant or via vessel-targeted nanosuspension delivery.
Type:
Grant
Filed:
December 29, 2022
Date of Patent:
July 2, 2024
Assignee:
APTORUM THERAPEUTICS LIMITED
Inventors:
Wai Yip Thomas Lee, Chung Sing Daniel Poon, Ka Lun Lai, Junzhe Huang, Ho Yin Li
Abstract: The present invention relates to carboxylic acid aromatic amides compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease as a sole agent or in combination with other active ingredients.
Type:
Grant
Filed:
September 17, 2021
Date of Patent:
July 2, 2024
Assignee:
Bayer Pharma Aktiengesellschaft
Inventors:
Stefan Bäurle, Adam James Davenport, Christopher Stimson, Jens Nagel, Nicole Schmidt, Andrea Rotgeri, Ina Gröticke, Alexandra Rausch, Juergen Klar, Thomas Dyrks
Abstract: Methods and compositions for potentiating the effect of an opioid analgesic in a patient undergoing or planning to undergo opioid analgesic therapy using a potentiating amount of iboga alkaloid or pharmaceutically acceptable salt and/or solvate thereof that does not prolong the patient's QT interval by more than about 50 milliseconds.
Abstract: Methods of treating or preventing cancer, diabetes, and/or obesity in a subject are provided. The methods comprise administering to a subject a therapeutically effective amount of an SLC25A1 inhibitor as described herein. Also provided herein are pharmaceutical compositions comprising an SLC25A1 inhibitor and a chemotherapeutic agent. Further provided herein are methods of inhibiting SLC25A1 in a cell.
Type:
Grant
Filed:
August 3, 2018
Date of Patent:
June 25, 2024
Assignees:
Georgetown University, George Mason University
Abstract: The present disclosure describes compounds and compositions that inhibit ?-glucuronidase activity, and methods for attenuating the side effects of one or more drugs and improving the efficacy of drugs by administration of selective ?-glucuronidase inhibitors.
Type:
Grant
Filed:
September 7, 2018
Date of Patent:
June 25, 2024
Assignee:
Symberix, Inc.
Inventors:
Francis X. Tavares, Bret D. Wallace, Ward Peterson
Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi.
Type:
Grant
Filed:
October 1, 2019
Date of Patent:
June 18, 2024
Assignee:
SYNGENTA PARTICIPATIONS AG
Inventors:
Farhan Bou Hamdan, Matthias Weiss, Laura Quaranta
Abstract: The present disclosure relates to methods for treating plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), comprising administering to a pediatric patient (e.g., 2 to 15 years of age) in need thereof mirdametinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 24, 2023
Date of Patent:
June 18, 2024
Assignee:
SPRINGWORKS THERAPEUTICS, INC.
Inventors:
Uchenna H Iloeje, Abraham J Langseth, Todd Shearer
Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
Type:
Grant
Filed:
December 2, 2020
Date of Patent:
June 11, 2024
Assignee:
Cardurion Pharmaceuticals, Inc.
Inventors:
Suzanne Buttar, Mateusz Pitak, Adam Ross Patterson, Samuel Alexander Stratford, Ioana Sovago, Jun Xu, Peng Zhou, Haojuan Wei, Kuangchu Dai
Abstract: Provided herein are methods of treating tuberous sclerosis complex in a subject in need thereof by administering to the subject compositions comprising an mGlu5 negative allosteric modulator (NAM), having the structure of Formula I:
Abstract: The present invention is in the field of agricultural pathogen control. More specifically the invention relates to compounds capable of inhibiting cinnamate-4-hydroxylase and their use for protecting plants against plant pathogens, in particular against nematodes, fungi and/or bacteria. The invention also provides for compositions comprising the same, methods of making the same, and methods of controlling plant disease.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
May 28, 2024
Assignees:
UNIVERSITEIT GENT, VIB VZW, TAMINCO BV
Inventors:
Willem Desmedt, Tina Kyndt, Bartel Vanholme
Abstract: The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability.
Type:
Grant
Filed:
May 10, 2023
Date of Patent:
May 28, 2024
Assignee:
Nanopharmaceutics, Inc.
Inventors:
James David Talton, Mianji Zhang, Lianhao Zhang, Otto Joseph Geoffroy, Daniel Gerard Morgan
Abstract: The present invention relates to diaminotriazine compounds and to their use as herbicides. It also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation.
Type:
Grant
Filed:
September 9, 2019
Date of Patent:
May 28, 2024
Assignee:
BASF SE
Inventors:
Danny Geerdink, Florian Vogt, Thomas Zierke, Martin Hartmueller, Trevor William Newton, Klaus Reinhard, Thomas Seitz
Abstract: The invention relates to new 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-indoles and 4-(piperazin-1-yl)-2-(trifluoromethyl)-1H-benzimidazoles represented by formula (I), wherein all symbols and variables are as defined in the description. The compounds can find use in a method of prevention and/or treatment of diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease, Lewy body dementia, dementia-related psychosis, schizophrenia, delusional syndromes and other psychotic conditions related and not related to taking psychoactive substances, depression, anxiety disorders of various aetiology, sleep disorders of various aetiology.
Type:
Grant
Filed:
May 20, 2021
Date of Patent:
May 14, 2024
Assignee:
ADAMED PHARMA S.A.
Inventors:
Marcin Kolaczkowski, Adam Bucki, Joanna Sniecikowska, Monika Marcinkowska